View 
FILTERS (0)
* Not connected to ResearchPool

MORE FILTERS

  
reports
Jonathan Moreland
  • Jonathan Moreland

InsiderInsights Weekly Report: February 14, 2026

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

Jonathan Moreland
  • Jonathan Moreland

InsiderInsights.com Daily Ratings Report: February 13, 2026

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

Prospect Capital Corp: 1 director

A director at Prospect Capital Corp bought 942,800 shares at 2.917USD and the significance rating of the trade was 79/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years...

 PRESS RELEASE

OPKO Health to Report Fourth Quarter 2025 Financial Results on Februar...

OPKO Health to Report Fourth Quarter 2025 Financial Results on February 26 MIAMI, Feb. 12, 2026 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) plans to report operating and financial results for the three and 12 months ended December 31, 2025, after the close of the U.S. financial markets on Thursday, February 26, 2026. OPKO’s senior management will provide a business update and discuss results as well as financial guidance during a conference call and live audio webcast beginning at 4:30 p.m. Eastern time. CONFERENCE CALL & WEBCAST INFORMATION OPKO encourages participants to pre-r...

Snap Inc: 1 director

A director at Snap Inc sold/gave away 2,601,453 shares at 0.000USD and the significance rating of the trade was 68/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years cl...

 PRESS RELEASE

Prospect Capital Announces Financial Results for December 2025

Prospect Capital Announces Financial Results for December 2025 NEW YORK, Feb. 09, 2026 (GLOBE NEWSWIRE) -- Prospect Capital Corporation (NASDAQ: PSEC) (“Prospect”, “our”, or “we”) today announced financial results for our fiscal quarter ended December 31, 2025. FINANCIAL RESULTS All amounts in $000’s exceptper share amounts (on weighted average basis for period numbers)Quarter EndedQuarter EndedQuarter Ended December 31, 2025September 30, 2025December 31, 2024    Net Investment Income (“NII”)$90,888$79,350$86,431NII per Common Share$0.19$0.17$0.20Interest as % of Total Investment Income8...

 PRESS RELEASE

Prospect Capital Schedules Second Fiscal Quarter Earnings Release and ...

Prospect Capital Schedules Second Fiscal Quarter Earnings Release and Conference Call NEW YORK, Feb. 06, 2026 (GLOBE NEWSWIRE) -- Prospect Capital Corporation (NASDAQ: PSEC) (the “Company” or “Prospect”) today announced it expects to file with the Securities and Exchange Commission its report on Form 10-Q containing results for the fiscal quarter ended December 31, 2025 and to issue its earnings press release on Monday, February 9, 2026, after the close of the markets. The Company will host a conference call on Tuesday, February 10, 2026 at 9:00 a.m. Eastern Time. The conference call dia...

 PRESS RELEASE

OPKO Health and Entera Bio Expand Partnership to Advance First-in-Clas...

OPKO Health and Entera Bio Expand Partnership to Advance First-in-Class Oral Long Acting PTH Tablet for Patients with Hypoparathyroidism This is the third program that successfully combines Entera’s oral peptide N-Tab® platform with OPKO’s advanced protein chemistry capabilities The companies have accelerated this program and aim to file an investigational new drug (IND) application in late 2026 Injectable and oral oxyntomodulin (dual GLP-1/glucagon analog) for metabolic and fibrotic disorders advancing with initial Phase 1 data from injectable oxyntomodulin (OXM) expected in late 2026; o...

 PRESS RELEASE

Prospect Capital Announces Annual Meeting Update

Prospect Capital Announces Annual Meeting Update NEW YORK, Jan. 08, 2026 (GLOBE NEWSWIRE) -- Prospect Capital Corporation (NASDAQ: PSEC) (“Prospect”, “our”, or “we”) today announced that it held its adjourned annual meeting of stockholders (the “Annual Meeting”) on January 8, 2026. The proposals that were considered at the Annual Meeting are described in detail in the Company’s definitive proxy statement for the Annual Meeting as filed with the Securities and Exchange Commission on September 18, 2025 (the “Proxy”). As of September 17, 2025, there were 465,087,009 shares of the Company's c...

 PRESS RELEASE

OPKO Health to Participate in the 44th Annual J.P. Morgan Healthcare C...

OPKO Health to Participate in the 44th Annual J.P. Morgan Healthcare Conference MIAMI, Jan. 06, 2026 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (Nasdaq: OPK) announced today that management will be participating in the 44th Annual J.P. Morgan Healthcare Conference, being held January 12-15, 2026, at the Westin St. Francis Hotel in San Francisco.  Management will be hosting one-on-one meetings with investors and will be participating in a fireside chat on Wednesday, January 14th at 1:30 p.m. Pacific time. The fireside chat will be webcast live and available for replay in the Investors sectio...

 PRESS RELEASE

Prospect Capital Announces Annual Meeting Update

Prospect Capital Announces Annual Meeting Update NEW YORK, Dec. 16, 2025 (GLOBE NEWSWIRE) -- Prospect Capital Corporation (NASDAQ: PSEC) (“Prospect”, “our”, or “we”) today announced that it held its annual meeting of stockholders (the “Annual Meeting”) on December 16, 2025. The proposals that were considered at the Annual Meeting are described in detail in the Company’s definitive proxy statement for the Annual Meeting as filed with the Securities and Exchange Commission on September 18, 2025 (the “Proxy”). As of September 17, 2025, there were 465,087,009 shares of the Company's common st...

Jonathan Moreland
  • Jonathan Moreland

Monthly Insider Special Screens: December 1, 2025

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

Opko Health Inc: 1 director

A director at Opko Health Inc bought 580,000 shares at 1.326USD and the significance rating of the trade was 67/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clear...

 PRESS RELEASE

OPKO Health to Participate in the Piper Sandler 37th Annual Healthcare...

OPKO Health to Participate in the Piper Sandler 37th Annual Healthcare Conference MIAMI, Nov. 19, 2025 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (Nasdaq: OPK) announced today that management will be participating in the Piper Sandler 37th Annual Healthcare Conference, being held December 2-4, 2025 at the Lotte New York Palace Hotel in New York City. Management will be holding one-on-one meetings with investors and will be participating in a fireside discussion on Wednesday, December 3rd at 12:00 p.m. Eastern time. Investors interested in scheduling a meeting with OPKO management should conta...

 PRESS RELEASE

Prospect Capital Announces Financial Results for September 2025

Prospect Capital Announces Financial Results for September 2025 NEW YORK, Nov. 06, 2025 (GLOBE NEWSWIRE) -- Prospect Capital Corporation (NASDAQ: PSEC) (“Prospect”, “our”, or “we”) today announced financial results for our fiscal quarter ended September 30, 2025. FINANCIAL RESULTS All amounts in $000’s exceptper share amounts (on weighted averagebasis for period numbers)Quarter EndedQuarter EndedQuarter EndedSeptember 30, 2025June 30, 2025September 30, 2024    Net Investment Income (“NII”)$79,350$79,043$89,877NII per Common Share$0.17$0.17$0.21Interest as % of Total Investmen...

Dan Salmon
  • Dan Salmon

Snap Inc. (SNAP, Neutral, $8 target) Revenue growth in-line, and Perpl...

What’s New: In this first take following tonight’s results, we focus on: 1. Stock pops on improved results and surprise Perplexity deal 2. DR recovers & continued enthusiasm for SMBs, but large advertisers down 3. North America DAUs steady but we remain cautious as age verification rolls out 4. Perplexity boosts the AI narrative 5. Very good cost control and margins

Loading...
New interest

Save your current filters as a new Interest

Please enter a name for this interest

Email alerts

Would you like to receive real-time email alerts when a new report is published under this interest?

Save This Search

These search results will show up under 'Saved searches' in the left panel

Please enter a name for this saved search

ResearchPool Subscriptions

Get the most out of your insights

Get in touch